Lyell Immunopharma (LYEL) Stock Price, News & Analysis

Company Overview

Lyell Immunopharma is a clinical-stage biotechnology company focused on developing next-generation cell therapies for the treatment of cancer. The company uses proprietary technologies to identify and reverse the epigenetic programs that drive T cell dysfunction, with the goal of producing more potent and durable immune responses against solid tumors and hematologic malignancies. Lyell’s platform integrates advanced cell engineering, manufacturing automation and translational biomarker programs to optimize T cell fitness and persistence in patients.

The company’s therapeutic pipeline includes autologous tumor-infiltrating lymphocyte (TIL) programs targeting melanoma and other solid tumors, as well as allogeneic chimeric antigen receptor (CAR) T cell candidates directed against hematologic cancers. Lyell’s lead candidates leverage epigenetic modulators to reprogram exhausted T cells and enhance their ability to seek out and destroy cancer cells. In parallel, the company is advancing novel combinatorial approaches that pair engineered cell therapies with immune checkpoint inhibitors and other targeted agents to broaden clinical benefit.

Founded in 2017 and headquartered in South San Francisco, Lyell Immunopharma was established by a team of researchers and executives with deep expertise in immuno-oncology and cell therapy development. Since its inception, the company has secured strategic collaborations with academic institutions and biopharmaceutical partners to accelerate its discovery efforts and scale its manufacturing processes. Lyell completed its initial public offering in 2020 and continues to expand its research and clinical operations.

Lyell serves patients and healthcare providers primarily in North America and Europe, with growing plans for global clinical trials and regulatory filings. The company’s leadership team comprises seasoned biotech professionals, including experts in translational research, clinical development, regulatory affairs and manufacturing. Together, they aim to establish Lyell as a leader in engineered cell therapies that offer new hope for patients with hard-to-treat cancers.

Key Stats

• Today's Range: $9.61 to $9.95
• 50-Day Range: $7.80 to $13.47
• 52-Week Range: $7.65 to $38.40
• Volume: 23,433 shs
• Average Volume: 72,742 shs
• Market Capitalization: $144.40 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $15.00
• Consensus Rating: Reduce

Lyell Immunopharma Stock Analysis - MarketRank™

Lyell Immunopharma scored higher than 70% of companies evaluated by MarketBeat, and ranked 317th out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.8 / 5
• Analyst Rating: Reduce

Consensus Rating

Lyell Immunopharma has received a consensus rating of Reduce. The company's average rating score is 1.50, and is based on no buy ratings, 1 hold rating, and 1 sell rating.

Amount of Analyst Coverage

Lyell Immunopharma has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Lyell Immunopharma are expected to grow in the coming year, from ($0.78) to ($0.70) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Lyell Immunopharma is -0.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Lyell Immunopharma is -0.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Lyell Immunopharma has a P/B Ratio of 0.37. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.00% of the float of Lyell Immunopharma has been sold short.

Short Interest Ratio / Days to Cover

Lyell Immunopharma has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Lyell Immunopharma has recently decreased by 26.65%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Lyell Immunopharma does not currently pay a dividend.

Dividend Growth

Lyell Immunopharma does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

4.00% of the float of Lyell Immunopharma has been sold short.

Short Interest Ratio / Days to Cover

Lyell Immunopharma has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Lyell Immunopharma has recently decreased by 26.65%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: N/A

News Sentiment

Lyell Immunopharma has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.99 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Lyell Immunopharma this week, compared to 2 articles on an average week.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Lyell Immunopharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

22.30% of the stock of Lyell Immunopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

66.05% of the stock of Lyell Immunopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

LYEL Stock Analysis - Frequently Asked Questions

How have LYEL shares performed this year?

Lyell Immunopharma's stock was trading at $12.80 at the start of the year. Since then, LYEL shares have decreased by 23.8% and is now trading at $9.75.

How were Lyell Immunopharma's earnings last quarter?

Lyell Immunopharma, Inc. (NASDAQ:LYEL) announced its quarterly earnings results on Tuesday, May, 13th. The company reported ($3.60) EPS for the quarter, beating the consensus estimate of ($3.80) by $0.20. The company earned $0.01 million during the quarter. Lyell Immunopharma had a negative trailing twelve-month return on equity of 73.66% and a negative net margin of 514,649.22%.

When did Lyell Immunopharma's stock split?

Lyell Immunopharma's stock reverse split on the morning of Friday, May 30th 2025.The 1-20 reverse split was announced on Friday, May 30th 2025. The number of shares owned by shareholders was adjusted after the market closes on Friday, May 30th 2025. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

When did Lyell Immunopharma IPO?

Lyell Immunopharma (LYEL) raised $425 million in an initial public offering on Thursday, June 17th 2021. The company issued 25,000,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, BofA Securities, J.P. Morgan and Morgan Stanley served as the underwriters for the IPO.

How do I buy shares of Lyell Immunopharma?

Shares of LYEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Lyell Immunopharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Lyell Immunopharma investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Netflix (NFLX), Broadcom (AVGO), Invesco QQQ (QQQ) and Palo Alto Networks (PANW).

Company Calendar

• Last Earnings: 5/13/2025
• Today: 7/13/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:LYEL
• CIK: 1806952
• Web: www.lyell.com
• Phone: 650-695-0677
• Fax: N/A
• Employees: 270
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Lyell Immunopharma: $15.00
• High Price Target: $20.00
• Low Price Target: $10.00
• Potential Upside/Downside: +53.8%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($25.00)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$342.99 million
• Net Margins: -514,649.22%
• Pretax Margin: -514,649.16%
• Return on Equity: -73.66%
• Return on Assets: -60.99%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.49
• Quick Ratio: 7.49

Sales & Book Value

• Annual Sales: $60 thousand
• Price / Sales: 2,406.63
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $26.21 per share
• Price / Book: 0.37

Miscellaneous

• Outstanding Shares: 14,810,000
• Free Float: 11,506,000
• Market Cap: $144.40 million
• Optionable: Optionable
• Beta: -0.24